Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $8.32 and traded as low as $5.84. Enanta Pharmaceuticals shares last traded at $5.88, with a volume of 166,938 shares changing hands.
Wall Street Analyst Weigh In
ENTA has been the topic of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. JMP Securities reaffirmed a "market outperform" rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, StockNews.com raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $17.25.
View Our Latest Stock Report on Enanta Pharmaceuticals
Enanta Pharmaceuticals Trading Down 2.6 %
The stock has a fifty day simple moving average of $6.41 and a two-hundred day simple moving average of $8.21. The company has a market cap of $121.81 million, a PE ratio of -1.15 and a beta of 0.48.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. As a group, equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.
Insider Activity
In other news, CEO Jay R. Luly purchased 45,000 shares of the firm's stock in a transaction dated Wednesday, February 12th. The shares were acquired at an average price of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares of the company's stock, valued at $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 13.89% of the company's stock.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at $26,000. Tower Research Capital LLC TRC increased its holdings in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 2,274 shares in the last quarter. Intech Investment Management LLC purchased a new position in Enanta Pharmaceuticals during the 4th quarter valued at about $58,000. Squarepoint Ops LLC acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth about $66,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $75,000. 94.99% of the stock is owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
(
Get Free Report)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Further Reading
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
